Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius

Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to ... Read More